1-11 of 11
Marcel B. Bally
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

In Vivo Validation of PAPSS1 (3′-phosphoadenosine 5′-phosphosulfate synthase 1) as a Cisplatin-sensitizing Therapeutic Target

Ada W.Y. Leung, Chansey J. Veinotte, Nicole Melong, Min Hee Oh, Kent Chen, Katey S.S. Enfield, Ian Backstrom, Corinna Warburton, Donald Yapp, Jason N. Berman, Marcel B. Bally, William W. Lockwood
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (21): 6555–6566.
https://doi.org/10.1158/1078-0432.CCR-17-0700
Published: 31 October 2017
View article titled, <em>In Vivo</em> Validation of PAPSS1 (3′-phosphoadenosine 5′-phosphosulfate synthase 1) as a Cisplatin-sensitizing Therapeutic Target
Open the PDF for <em>In Vivo</em> Validation of PAPSS1 (3′-phosphoadenosine 5′-phosphosulfate synthase 1) as a Cisplatin-sensitizing Therapeutic Target in another window
Includes: Supplementary data
Journal Articles

Autophagy Inhibition Augments the Anticancer Effects of Epirubicin Treatment in Anthracycline-Sensitive and -Resistant Triple-Negative Breast Cancer

Suganthi Chittaranjan, Svetlana Bortnik, Wieslawa H. Dragowska, Jing Xu, Namal Abeysundara, Amy Leung, Nancy E. Go, Lindsay DeVorkin, Sherry A. Weppler, Karen Gelmon, Donald T. Yapp, Marcel B. Bally, Sharon M. Gorski
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (12): 3159–3173.
https://doi.org/10.1158/1078-0432.CCR-13-2060
Published: 12 June 2014
View article titled, Autophagy Inhibition Augments the Anticancer Effects of Epirubicin Treatment in Anthracycline-Sensitive and -Resistant Triple-Negative Breast Cancer
Open the PDF for Autophagy Inhibition Augments the Anticancer Effects of Epirubicin Treatment in Anthracycline-Sensitive and -Resistant Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Topotecan and Doxorubicin Combination to Treat Recurrent Ovarian Cancer: The Influence of Drug Exposure Time and Delivery Systems to Achieve Optimum Therapeutic Activity

Nilesh A. Patankar, Julia Pritchard, Mariska van Grinsven, Maryam Osooly, Marcel B. Bally
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (4): 865–877.
https://doi.org/10.1158/1078-0432.CCR-12-2459
Published: 14 February 2013
View article titled, Topotecan and Doxorubicin Combination to Treat Recurrent Ovarian Cancer: The Influence of Drug Exposure Time and Delivery Systems to Achieve Optimum Therapeutic Activity
Open the PDF for Topotecan and Doxorubicin Combination to Treat Recurrent Ovarian Cancer: The Influence of Drug Exposure Time and Delivery Systems to Achieve Optimum Therapeutic Activity in another window
Includes: Supplementary data
Journal Articles

Irinophore C, a Novel Nanoformulation of Irinotecan, Alters Tumor Vascular Function and Enhances the Distribution of 5-Fluorouracil and Doxorubicin

Jennifer H.E. Baker, Jeffrey Lam, Alaistair H. Kyle, Jonathan Sy, Thomas Oliver, Steven J. Co, Wieslawa H. Dragowska, Euan Ramsay, Malathi Anantha, Thomas J. Ruth, Michael J. Adam, Andrew Yung, Piotr Kozlowski, Andrew I. Minchinton, Sylvia S.W. Ng, Marcel B. Bally, Donald T.T. Yapp
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (22): 7260–7271.
https://doi.org/10.1158/1078-0432.CCR-08-0736
Published: 14 November 2008
View article titled, Irinophore C, a Novel Nanoformulation of Irinotecan, Alters Tumor Vascular Function and Enhances the Distribution of 5-Fluorouracil and Doxorubicin
Open the PDF for Irinophore C, a Novel Nanoformulation of Irinotecan, Alters Tumor Vascular Function and Enhances the Distribution of 5-Fluorouracil and Doxorubicin in another window
Journal Articles

Irinophore C: A Liposome Formulation of Irinotecan with Substantially Improved Therapeutic Efficacy against a Panel of Human Xenograft Tumors

Euan C. Ramsay, Malathi Anantha, Jason Zastre, Marieke Meijs, Jet Zonderhuis, Dita Strutt, Murray S. Webb, Dawn Waterhouse, Marcel B. Bally
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (4): 1208–1217.
https://doi.org/10.1158/1078-0432.CCR-07-0780
Published: 15 February 2008
View article titled, Irinophore C: A Liposome Formulation of Irinotecan with Substantially Improved Therapeutic Efficacy against a Panel of Human Xenograft Tumors
Open the PDF for Irinophore C: A Liposome Formulation of Irinotecan with Substantially Improved Therapeutic Efficacy against a Panel of Human Xenograft Tumors in another window
Journal Articles

Antitumor Efficacy of Oblimersen Bcl-2 Antisense Oligonucleotide Alone and in Combination with Vinorelbine in Xenograft Models of Human Non–Small Cell Lung Cancer

YanPing Hu, Gwyn Bebb, Sophia Tan, Rebecca Ng, Hong Yan, Jason R. Sartor, Lawrence D. Mayer, Marcel B. Bally
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (22): 7662–7670.
https://doi.org/10.1158/1078-0432.CCR-04-1036
Published: 29 November 2004
View article titled, Antitumor Efficacy of Oblimersen Bcl-2 Antisense Oligonucleotide Alone and in Combination with Vinorelbine in Xenograft Models of Human Non–Small Cell Lung Cancer
Open the PDF for Antitumor Efficacy of Oblimersen Bcl-2 Antisense Oligonucleotide Alone and in Combination with Vinorelbine in Xenograft Models of Human Non–Small Cell Lung Cancer in another window
Journal Articles

Liposomal Irinotecan: Formulation Development and Therapeutic Assessment in Murine Xenograft Models of Colorectal Cancer

Corrie Lynn Messerer, Euan C. Ramsay, Dawn Waterhouse, Rebecca Ng, Eva-Maria Simms, Natashia Harasym, Paul Tardi, Lawrence D. Mayer, Marcel B. Bally
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (19): 6638–6649.
https://doi.org/10.1158/1078-0432.CCR-04-0221
Published: 08 October 2004
View article titled, Liposomal Irinotecan: <subtitle>Formulation Development and Therapeutic Assessment in Murine Xenograft Models of Colorectal Cancer</subtitle>
Open the PDF for Liposomal Irinotecan: <subtitle>Formulation Development and Therapeutic Assessment in Murine Xenograft Models of Colorectal Cancer</subtitle> in another window
Journal Articles

Treatment of HER-2/ neu Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/ neu and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction

Corinna Warburton, Wieslawa H. Dragowska, Karen Gelmon, Stephen Chia, Hong Yan, Dana Masin, Tetyana Denyssevych, Anne E. Wallis, Marcel B. Bally
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (7): 2512–2524.
https://doi.org/10.1158/1078-0432.CCR-03-0244
Published: 08 April 2004
View article titled, Treatment of HER-2/ <em>neu</em> Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/ <em>neu</em> and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction
Open the PDF for Treatment of HER-2/ <em>neu</em> Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/ <em>neu</em> and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction in another window
Journal Articles

In Vitro and in Vivo Characterization of Doxorubicin and Vincristine Coencapsulated within Liposomes through Use of Transition Metal Ion Complexation and pH Gradient Loading

Sheela A. Abraham, Cheryl McKenzie, Dana Masin, Rebecca Ng, Troy O. Harasym, Lawrence D. Mayer, Marcel B. Bally
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (2): 728–738.
https://doi.org/10.1158/1078-0432.CCR-1131-03
Published: 03 February 2004
View article titled, <em>In Vitro</em> and <em>in Vivo</em> Characterization of Doxorubicin and Vincristine Coencapsulated within Liposomes through Use of Transition Metal Ion Complexation and pH Gradient Loading
Open the PDF for <em>In Vitro</em> and <em>in Vivo</em> Characterization of Doxorubicin and Vincristine Coencapsulated within Liposomes through Use of Transition Metal Ion Complexation and pH Gradient Loading in another window
Journal Articles

Kupffer Cells Do Not Play a Role in Governing the Efficacy of Liposomal Mitoxantrone Used to Treat a Tumor Model Designed to Assess Drug Delivery to Liver

Howard J. Lim, Michael J. Parr, Dana Masin, Natashia L. McIntosh, Thomas D. Madden, Guoyang Zhang, Sharon Johnstone, Marcel B. Bally
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (11): 4449–4460.
Published: 01 November 2000
View article titled, Kupffer Cells Do Not Play a Role in Governing the Efficacy of Liposomal Mitoxantrone Used to Treat a Tumor Model Designed to Assess Drug Delivery to Liver
Open the PDF for Kupffer Cells Do Not Play a Role in Governing the Efficacy of Liposomal Mitoxantrone Used to Treat a Tumor Model Designed to Assess Drug Delivery to Liver in another window
Journal Articles

Eradication of Human Non-Hodgkin’s Lymphoma in SCID Mice by BCL-2 Antisense Oligonucleotides Combined with Low-Dose Cyclophosphamide

Richard J. Klasa, Marcel B. Bally, Rebecca Ng, James H. Goldie, Randy D. Gascoyne, Frances M. P. Wong
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (6): 2492–2500.
Published: 01 June 2000
View article titled, Eradication of Human Non-Hodgkin’s Lymphoma in SCID Mice by BCL-2 Antisense Oligonucleotides Combined with Low-Dose Cyclophosphamide
Open the PDF for Eradication of Human Non-Hodgkin’s Lymphoma in SCID Mice by BCL-2 Antisense Oligonucleotides Combined with Low-Dose Cyclophosphamide in another window